← Analyst Upside
AU · rank #3 · 2026-09-07
NUTX
NASDAQ · $1.31B (USD)
SignalHold
verdict · CAUTION
The exact numbers the algorithm saw.
| Composite score Z-score blend of all factors below. | 3.116 |
|---|---|
| EPS revisions (30d) Change in consensus EPS estimate over the past 30 days ($/share). | +$4.84 |
| Net revisions (30d) Number of analysts revising upward minus downward. | 5 |
| Insider signal (90d) $0 across 0 unique buyers. | -0.159 |
| Analyst upside Consensus target $276.00 | +42.8% |
| Momentum acceleration 3-month minus 12-month momentum. | +9.78% |
| Analyst rating 5 = Strong Buy, 1 = Strong Sell. | 4.67 |
| Gross margin TTM | +54.5% |
| 52w high | $204.00 |
| Market cap (USD) | $1.31B |
The AI research card
Independent qualitative review of each pick before the order is placed. On the rare day the research service is unavailable, the paper book trades on the quant ranking alone and no card appears here.
Summary
Nutex Health Inc. operates a network of 27 physician-led micro-hospitals and outpatient facilities across 12 states alongside risk-bearing primary care networks.
Rationale
The company's dramatic swing to Q2 2026 profitability with a $9.38 diluted EPS justifies the massive 89.3% earnings surprise and validates the unanimous analyst upward revisions.
Material risks
- 1Regulatory pressure and potential billing rate compression resulting from the Fifth Circuit's rejection of "ghost rates" in federal QPA calculations under the No Surprises Act.
- 2Profitability gains are heavily dependent on temporary cost reductions, such as lower contract services expenses and reduced stock compensation, rather than scalable revenue growth.
AI verdict council
Each pick is reviewed independently by 3 models before any order. 1 of 3 voted to proceed.
OpenAI
Caution
Claude
Caution
Gemini
Proceed